Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

Fig. 1

Balb/c mice immunized with RBD-Fc produced SARS-CoV-2 RBD- and S1-specific antibodies. a The immunization protocols. b, c Detection of the SARS-CoV-2 RBD-specific IgG in different dilutions of sera from day 21 (b) and the RBD-specific IgG titer in sera from day 21 (c) using ELISA assay. d, e Detection of the SARS-CoV-2 S1-specific IgG in different dilutions of sera from day 21 (d) and the S1-specific IgG titer in sera from day 21 (e) using ELISA assay. f, g The binding capacity of the total IgG in the sera from day 35 to SARS-CoV-2 RBD (f) and the SARS-CoV-2 RBD-specific total IgG titer (g). h, i The binding capacity of IgG in the sera from day 35 to SARS-CoV-2 S1 (h) and SARS-CoV-2 S1-specific IgG titer (i). Data shown are geometric mean ± SD from six samples. All experiments were repeated at least twice

Back to article page